Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes overwhelming, causing widespread inflammation and damage to its own tissues and organs. Sepsis and septic shock remain major global health challenges, with sepsis associated with approximately 20% of deaths worldwide.
Fanfei Meng, Ph.D., 91视频 College of Pharmacy (UHCOP) Assistant Professor and Presidential Frontier Faculty member, has received a $446,144 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance a promising new approach to sepsis treatment. His research addresses two critical challenges simultaneously: eliminating harmful bacterial infections and controlling excessive immune responses that can lead to life-threatening complications.
Tackling Two Major Challenges in Sepsis Treatment
Antibiotics are essential for treating bacterial infections that cause sepsis, but eliminating bacteria alone may not fully resolve the condition. Even after bacteria are killed, bacterial components can remain in the body and continue stimulating harmful inflammatory responses, potentially contributing to organ damage and worsening clinical outcomes.
Meng's research seeks to overcome this challenge through an innovative nanoparticle-based drug delivery system that combines two complementary therapeutic approaches into a single treatment.
The experimental therapy incorporates an antibacterial agent to combat infection and an immunomodulatory agent designed to regulate excessive inflammatory responses. By delivering these agents together using a specially engineered nanoparticle platform, the researchers aim to enhance therapeutic effectiveness while potentially reducing treatment-related toxicity.
"We want the immune system to remain strong enough to protect the body without overreacting to the bacteria," Meng said.
This dual-action strategy could offer a new approach to sepsis treatment by addressing both the underlying infection and the potentially damaging inflammatory response.
Promising Results in Early Studies
Preliminary laboratory and animal studies have produced encouraging results, suggesting that the nanoparticle-based treatment may improve therapeutic outcomes while reducing adverse effects associated with conventional drug administration.
In early experiments, the treatment demonstrated antibacterial activity, helped regulate excessive inflammatory responses and showed improved tolerability.
In a preclinical model of severe inflammation triggered by bacterial components, researchers observed a 100% survival rate among treated animals. In a separate, more challenging model involving bacterial infection within the abdominal cavity, the treatment achieved a 90% survival rate.
Although these findings are promising, they represent early-stage preclinical results, and further research is needed to determine whether similar benefits can be achieved in humans.
Advancing Toward Future Sepsis Therapies
With support from the new NIAID grant, Meng and his research team will further investigate the safety, effectiveness, and biological behavior of the nanoparticle-based treatment.
The project will focus on how the therapeutic nanoparticles are distributed and eliminated from the body, evaluate their safety profiles, and determine their effectiveness in additional preclinical sepsis models. The team will also investigate how the combined treatment combats bacterial infections while regulating excessive inflammatory responses.
Beyond sepsis, the research may offer valuable insights into developing combination therapies using advanced drug-delivery technologies.
"We're excited about the promise of this technology," Meng said. "While there's still important work ahead, we hope our research will ultimately lead to better treatment options for patients with sepsis."
Although still in the early stages of development, this research represents a promising step toward a new therapeutic approach that addresses both infection and harmful inflammation, with the ultimate goal of improving outcomes for patients with sepsis.